ZA896149B - Pharmaceutical formulation for the treatment of diabetes mellitus - Google Patents

Pharmaceutical formulation for the treatment of diabetes mellitus

Info

Publication number
ZA896149B
ZA896149B ZA896149A ZA896149A ZA896149B ZA 896149 B ZA896149 B ZA 896149B ZA 896149 A ZA896149 A ZA 896149A ZA 896149 A ZA896149 A ZA 896149A ZA 896149 B ZA896149 B ZA 896149B
Authority
ZA
South Africa
Prior art keywords
treatment
diabetes mellitus
arg
insulin
pharmaceutical formulation
Prior art date
Application number
ZA896149A
Other languages
English (en)
Inventor
Michael Boerschug
Boerschug Michael
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of ZA896149B publication Critical patent/ZA896149B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA896149A 1988-08-13 1989-08-11 Pharmaceutical formulation for the treatment of diabetes mellitus ZA896149B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3827533A DE3827533A1 (de) 1988-08-13 1988-08-13 Pharmazeutische zubereitung zur behandlung des diabetes mellitus

Publications (1)

Publication Number Publication Date
ZA896149B true ZA896149B (en) 1990-04-25

Family

ID=6360797

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA896149A ZA896149B (en) 1988-08-13 1989-08-11 Pharmaceutical formulation for the treatment of diabetes mellitus

Country Status (18)

Country Link
US (1) US5177058A (xx)
EP (1) EP0357978B1 (xx)
JP (1) JPH02101022A (xx)
KR (1) KR900002801A (xx)
AT (1) ATE75945T1 (xx)
AU (1) AU621648B2 (xx)
CA (1) CA1332354C (xx)
DE (2) DE3827533A1 (xx)
DK (1) DK395689A (xx)
ES (1) ES2039773T3 (xx)
FI (1) FI95202C (xx)
GR (1) GR3005326T3 (xx)
HU (1) HU203670B (xx)
IE (1) IE61266B1 (xx)
NO (1) NO178914C (xx)
NZ (1) NZ230280A (xx)
PT (1) PT91420B (xx)
ZA (1) ZA896149B (xx)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875589B1 (en) * 1988-06-23 2005-04-05 Hoechst Aktiengesellschaft Mini-proinsulin, its preparation and use
DE4024434A1 (de) * 1990-08-01 1992-02-13 Fresenius Ag Vorrichtung zur ultrafiltrationskontrolle bzw. ultrafiltrationsregelung bei blutreinigungsverfahren
HU225496B1 (en) * 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
US5534488A (en) * 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
AR002976A1 (es) * 1995-03-31 1998-05-27 Lilly Co Eli Formulaciones farmaceuticas parenterales de efecto prolongado de insulina; cristales de dichos analogos aplicables en dichas formulaciones yprocedimiento de las formulaciones mencionadas
DE59711533D1 (de) 1996-07-26 2004-05-27 Aventis Pharma Gmbh Insulinderivate mit erhöhter Zinkbindung
AU1870099A (en) * 1998-01-09 1999-07-26 Novo Nordisk A/S Stabilised insulin compositions
DE19825447A1 (de) 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
SK2432004A3 (sk) * 2001-12-20 2005-04-01 Eli Lilly And Company Inzulínová zlúčenina s protrahovaným účinkom
DE10227232A1 (de) * 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
AU2004234345A1 (en) * 2003-04-29 2004-11-11 Eli Lilly And Company Insulin analogs having protracted time action
EP2264065B1 (en) * 2003-08-05 2017-03-08 Novo Nordisk A/S Novel insulin derivatives
CN105801686B (zh) 2004-07-19 2020-04-07 比奥孔有限公司 胰岛素-低聚物共轭物、制剂及其用途
CN101389650B (zh) * 2005-12-28 2012-10-10 诺沃-诺迪斯克有限公司 包含酰化胰岛素和锌的组合物以及制备所述组合物的方法
WO2008152106A1 (en) * 2007-06-13 2008-12-18 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
EP2203181B1 (en) * 2007-10-16 2018-02-14 Biocon Limited An orally administerable solid pharmaceutical composition and a process thereof
EP3228320B1 (de) 2008-10-17 2019-12-18 Sanofi-Aventis Deutschland GmbH Kombination von einem insulin und einem glp-1-agonisten
ES2607003T3 (es) * 2008-10-30 2017-03-28 Novo Nordisk A/S Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyección inferior a la diaria
UY33025A (es) 2009-11-13 2011-06-30 Sanofi Aventis Deustschland Gmbh Composicion farmaceutica que comprende un agonista de glp-1 metionina
AR080669A1 (es) 2009-11-13 2012-05-02 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina
MX339614B (es) 2010-08-30 2016-06-02 Sanofi - Aventis Deutschland GmbH Uso de ave0010 para la fabricacion de un medicamento para el tratamiento de la diabetes mellitus tipo 2.
BR112013010345A2 (pt) 2010-10-27 2017-07-25 Novo Nordisk As tratamento de diabetes melitus usando as injeções de insulina administradas com intervalos de variação da injeção
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
RU2650616C2 (ru) 2011-08-29 2018-04-16 Санофи-Авентис Дойчланд Гмбх Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
CN107206058A (zh) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 甘精胰岛素/利西拉来固定比率配制剂
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2143591A (en) * 1936-09-26 1939-01-10 Univ Alberta Therapeutic preparation and process of making and using it
US2354211A (en) * 1940-07-02 1944-07-25 Burroughs Wellcome Co Insulin preparation
DOP1982004086A (es) * 1981-08-27 1988-03-22 Lilly Co Eli Formula farmaceutica que comprende insulina humana y proinsulina humana
DE3326472A1 (de) * 1983-07-22 1985-02-14 Hoechst Ag, 6230 Frankfurt Neue insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DE3326473A1 (de) * 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
DE3333640A1 (de) * 1983-09-17 1985-04-25 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von insulin-derivaten, deren b-kette c-terminal verlaengert ist, neue basisch modifizierte insulin-derivate diese enthaltende mittel und ihre verwendung
DE3334407A1 (de) * 1983-09-23 1985-04-04 Hoechst Ag, 6230 Frankfurt In position b 30 modifizierte insulin-derivate, verfahren zu deren herstellung und deren verwendung sowie pharmazeutische mittel zur behandlung des diabetes mellitus
DK347086D0 (da) * 1986-07-21 1986-07-21 Novo Industri As Novel peptides
DK113585D0 (da) * 1985-03-12 1985-03-12 Novo Industri As Nye peptider

Also Published As

Publication number Publication date
US5177058A (en) 1993-01-05
KR900002801A (ko) 1990-03-23
IE61266B1 (en) 1994-10-19
GR3005326T3 (xx) 1993-05-24
FI893783A0 (fi) 1989-08-10
CA1332354C (en) 1994-10-11
DE3827533A1 (de) 1990-02-15
ES2039773T3 (es) 1996-07-16
NZ230280A (en) 1991-09-25
NO178914C (no) 1996-07-03
ATE75945T1 (de) 1992-05-15
DK395689D0 (da) 1989-08-11
NO893239L (no) 1990-02-14
DE58901401D1 (de) 1992-06-17
AU3951489A (en) 1990-02-15
DK395689A (da) 1990-02-14
NO178914B (no) 1996-03-25
EP0357978B1 (de) 1992-05-13
FI95202B (fi) 1995-09-29
FI893783A (fi) 1990-02-14
PT91420A (pt) 1990-03-08
JPH02101022A (ja) 1990-04-12
HU203670B (en) 1991-09-30
NO893239D0 (no) 1989-08-11
EP0357978A1 (de) 1990-03-14
PT91420B (pt) 1995-05-04
HUT50443A (en) 1990-02-28
FI95202C (fi) 1996-01-10
IE892594L (en) 1990-02-13
AU621648B2 (en) 1992-03-19

Similar Documents

Publication Publication Date Title
ZA896149B (en) Pharmaceutical formulation for the treatment of diabetes mellitus
EP0552256A4 (xx)
EP1234586A3 (en) Hepatoselective pharmaceutical actives
IL85523A (en) Stable alpha interferon complex,its preparation and pharmaceutical compositions comprising it
ZA845621B (en) Pharmaceutical agent for the treatment of diabetes mellitus
DK642587A (da) Insulinpraeparat
WO1996024370B1 (en) Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin
GR3006815T3 (xx)
AU7284098A (en) Method for preventing gastritis using amylin or amylin agonists
AU3318389A (en) Azelastine-containing medicaments with controlled release of the active substance
AU8687391A (en) Lithium treatment
AU6788687A (en) A pharmaceutical which can be administered nasally, a process for its preparation, and its use
GR3002765T3 (en) New pharmaceutical compositions for parenteral use containing a calcitonin as the active ingredient
AU536582B2 (en) Plenylpiperazine derivatives of 1,3,4-oxiadiazolylphends
EP0384302A3 (en) Use of ubenimex in the manufacture of a medicament for treating myelodysplastic syndrome
BR9006746A (pt) Peptideo fisiologicamente ativo e agente regulador do metabolismo de calcio
IT1264428B1 (it) Composizioni farmaceutiche per il trattamento della psoriasi
IT1259140B (it) Formulazioni farmaceutiche per la somministraziane orale di calcitonina
IT1263754B (it) Composizione farmaceutica per il trattamento della adiposita' localizzata e della cellulite a base di efedrina e caffeina